Discovery of a Highly Conserved Peptide in the Iron Transporter Melanotransferrin that Traverses an Intact Blood Brain Barrier and Localizes in Neural Cells
- PMID: 34149342
- PMCID: PMC8212695
- DOI: 10.3389/fnins.2021.596976
Discovery of a Highly Conserved Peptide in the Iron Transporter Melanotransferrin that Traverses an Intact Blood Brain Barrier and Localizes in Neural Cells
Abstract
The blood-brain barrier (BBB) hinders the distribution of therapeutics intended for treatment of diseases of the brain. Our previous studies demonstrated that that a soluble form of melanotransferrin (MTf; Uniprot P08582; also known as p97, MFI2, and CD228), a mammalian iron-transport protein, is an effective carrier for delivery of drug conjugates across the BBB into the brain and was the first BBB targeting delivery system to demonstrate therapeutic efficacy within the brain. Here, we performed a screen to identify peptides from MTf capable of traversing the BBB. We identified a highly conserved 12-amino acid peptide, termed MTfp, that retains the ability to cross the intact BBB intact, distributes throughout the parenchyma, and enter endosomes and lysosomes within neurons, astrocytes and microglia in the brain. This peptide may provide a platform for the transport of therapeutics to the CNS, and thereby offers new avenues for potential treatments of neuropathologies that are currently refractory to existing therapies.
Keywords: MTfp; blood-brain barrer; drug delivery and targeting; glial targeting; melanotransferrin; microglial targeting; neuronal targeting; peptide transport.
Copyright © 2021 Singh, Eyford, Abraham, Munro, Choi, Okon, Vitalis, Gabathuler, Lu, Pfeifer, Tian and Jefferies.
Conflict of interest statement
Bioasis Technologies Inc., (BTI) is a University of British Columbia start-up company. TZV, RG, and MMT were employees and equity holders in BTI at the time this work was undertaken. WAJ was the founding scientist and an equity holder in BTI at the time this work was undertaken. The funding sources had no influence in the study design, data collection, analysis or interpretation of data, in the writing of the manuscript or on the decision to submit for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



References
-
- Alemany R., Vila M. R., Franci C., Egea G., Real F. X., Thomson T. M. (1993). Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. J. Cell Sci. 104 1155–1162. - PubMed
-
- Baker E. N., Baker H. M., Smith C. A., Stebbins M. R., Kahn M., Hellstrom K. E., et al. (1992). Human melanotransferrin (p97) has only one functional iron-binding site. FEBS Lett. 298 215–218. - PubMed
-
- Baker_Lab Robetta is a Protein Structure Prediction Service that is Continually Evaluated Through CAMEO. Seattle, WA: Baker_Lab. (accessed 2015).
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous